The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR Convergence 2020: Study Data for Lupus & Rheumatoid Arthritis

ACR Convergence 2020: Study Data for Lupus & Rheumatoid Arthritis

November 9, 2020 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2020—At the annual meeting’s second Plenary Session, Saturday, Nov. 7, speakers highlighted phase 2 results of a potential new biologic for systemic lupus erythematosus (SLE), as well as data on remission maintenance in rheumatoid arthritis (RA) after withdrawal of etanercept or methotrexate.

You Might Also Like
  • Top Research in Lupus Presented at ACR Convergence 2020
  • ACR Convergence 2020: Studies in Rheumatoid Arthritis
  • Dr. Blair Solow’s Picks for the Top RA Research Presented at ACR Convergence 2020
Explore This Issue
December 2020
Also By This Author
  • Study: Can Avacopan Replace Steroids in ANCA-Associated Vasculitis?

Phase 2 Trial of Monoclonal Antibody for Lupus (LILAC)
Several converging lines of evidence suggest type I interferons play a key role in the pathogenesis of lupus, including recent trials demonstrating clinical effectiveness of anifrolumab, a monoclonal antibody that blocks the type I interferon receptor. Richard Furie, MD, chief of the Division of Rheumatology at Northwell Health, in Great Neck, N.Y., presented promising results from a phase II trial of a different monoclonal antibody, BIIBO59, which interfaces with the pathway through another mechanism.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Plasmacytoid dendritic cells are responsible for the bulk of type I interferon production in lupus and are abundant in the skin of lupus patients. BIIBO59 is an antibody to a protein unique to these cells, blood dendritic cell antigen 2 (BDCA2). The binding and internalization of the antibody results in inhibition of type I interferon, but also of various cytokines and chemokines, such as IL-6 and TNF-α.

An earlier phase I study of 12 lupus patients with cutaneous disease had demonstrated inhibition of the interferon gene signature, downregulation of an interferon-regulated protein and clinical improvement in skin activity as measured by the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A).2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Participants in the LILAC trial met at least four of the 11 ACR classification criteria, with at least four tender and at least four swollen joints (via 28-joint assessment), active skin disease as defined by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and positive serology. Sixty-four patients were randomized to receive BIIB059 mg, with another 56 receiving placebo. These were administered every four weeks for 20 weeks, with an additional dose at week two.

Dr. Furie

Dr. Furie noted the trial met its primary endpoint: “Receipt of BIIB059 was associated with significant reduction in the total active joint count.”

Moreover, the patient group receiving BIIB059 demonstrated a statistically significant improvement in their SLE Responder Index-4 (SRI-4) response rate. Dr. Furie observed, “Like most other [lupus] trials, the driver of the significant and robust SRI response was the four point reduction in SLEDAI.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

A higher number of patients in the BIIB059 group also achieved a 50% reduction in their CLASI-A score, although this did not reach statistical significance. Safety signals were similar between the placebo and treatment groups.

Pages: 1 2 3 4 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports, Rheumatoid Arthritis, SLE (Lupus) Tagged With: ACR Convergence 2020, ACR Convergence 2020 - SLE, ACR Convergence 2020 – RAIssue: December 2020

You Might Also Like:
  • Top Research in Lupus Presented at ACR Convergence 2020
  • ACR Convergence 2020: Studies in Rheumatoid Arthritis
  • Dr. Blair Solow’s Picks for the Top RA Research Presented at ACR Convergence 2020
  • ACR Convergence 2020 Kicks Off: Plenary session speakers highlight racial differences in lupus & COVID-19-related findings

About Ruth Jessen Hickman, MD

Ruth Jessen Hickman, MD, was born and raised in eastern Kentucky, where she first cultivated her love of literature, writing and personal narratives. She attended Kenyon college, where she received a Bachelor of Arts in philosophy, summa cum laude. She worked with individuals with psychiatric conditions and later in a neuroscience lab at the University of Illinois, Chicago, before graduating from Indiana University Medical School in 2011. Instead of pursuing clinical medicine, Ruth opted to build on her strength of clearly explaining medical topics though a career as a freelance medical writer, writing both for lay people and for health professionals. She writes across the biomedical sciences, but holds strong interests in rheumatology, neurology, autoimmune diseases, genetics, and the intersection of broader social, cultural and emotional contexts with biomedical topics. Ruth now lives in Bloomington, Ind., with her husband, son and cat. She can be contacted via her website at ruthjessenhickman.com.

View more by this author»

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)